Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells.
ALK inhibitors
alectinib
anaplastic lymphoma kinase (ALK)
crizotinib
neuroblastoma
resistant mutations
xenograft
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
29
01
2019
accepted:
14
06
2019
entrez:
24
7
2019
pubmed:
25
7
2019
medline:
25
7
2019
Statut:
epublish
Résumé
Oncogenic receptor tyrosine kinases including anaplastic lymphoma kinase (ALK) are implicated in numerous solid and hematologic cancers. ALK mutations are reported in an estimated 9% of neuroblastoma and recent reports indicate that the percentage of ALK-positive cases increases in the relapsed patient population. Initial clinical trial results have shown that it is difficult to inhibit growth of ALK positive neuroblastoma with crizotinib, motivating investigation of next generation ALK inhibitors with higher affinity for ALK. Here, alectinib, a potent next generation ALK inhibitor with antitumor activity was investigated in ALK-driven neuroblastoma models. Employing neuroblastoma cell lines and mouse xenografts we show a clear and efficient inhibition of ALK activity by alectinib. Inhibition of ALK activity was observed
Identifiants
pubmed: 31334113
doi: 10.3389/fonc.2019.00579
pmc: PMC6625372
doi:
Types de publication
Journal Article
Langues
eng
Pagination
579Références
J Biol Chem. 2005 Jul 15;280(28):26039-48
pubmed: 15886198
FEBS Lett. 2007 Feb 20;581(4):727-34
pubmed: 17274988
Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22
pubmed: 18089725
Nature. 2008 Oct 16;455(7215):930-5
pubmed: 18724359
Nature. 2008 Oct 16;455(7215):967-70
pubmed: 18923523
Nature. 2008 Oct 16;455(7215):971-4
pubmed: 18923524
Nature. 2008 Oct 16;455(7215):975-8
pubmed: 18923525
Biochem J. 2008 Dec 1;416(2):153-9
pubmed: 18990089
Biochim Biophys Acta. 2010 Mar;1804(3):440-4
pubmed: 19879387
Proc Natl Acad Sci U S A. 2010 Mar 2;107(9):4323-8
pubmed: 20145112
N Engl J Med. 2010 Jun 10;362(23):2202-11
pubmed: 20558371
Trends Biochem Sci. 2011 Feb;36(2):65-77
pubmed: 20971646
N Engl J Med. 2010 Oct 28;363(18):1693-703
pubmed: 20979469
N Engl J Med. 2010 Oct 28;363(18):1734-9
pubmed: 20979473
Cancer Res. 2011 Jan 1;71(1):98-105
pubmed: 21059859
Cancer Cell. 2011 May 17;19(5):679-90
pubmed: 21575866
Biochem J. 2011 Dec 15;440(3):405-13
pubmed: 21838707
Bioorg Med Chem. 2012 Feb 1;20(3):1271-80
pubmed: 22225917
Oncogene. 2012 Nov 1;31(44):4667-76
pubmed: 22249260
Oncogene. 2012 Dec 13;31(50):5193-200
pubmed: 22286764
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Dis Model Mech. 2013 Mar;6(2):373-82
pubmed: 23104988
Cancer Res. 2013 Jan 1;73(1):195-204
pubmed: 23139213
Pediatr Blood Cancer. 2013 Jun;60(6):985-93
pubmed: 23255319
Nat Genet. 2013 Mar;45(3):279-84
pubmed: 23334666
Lancet Oncol. 2013 May;14(6):472-80
pubmed: 23598171
Lancet Oncol. 2013 Jun;14(7):590-8
pubmed: 23639470
Nat Rev Cancer. 2013 Oct;13(10):685-700
pubmed: 24060861
J Clin Oncol. 2013 Nov 1;31(31):3987-96
pubmed: 24101047
Cancer Lett. 2014 Sep 1;351(2):215-21
pubmed: 24887559
J Clin Oncol. 2014 Sep 1;32(25):2727-34
pubmed: 25071110
Genes Chromosomes Cancer. 2015 Feb;54(2):99-109
pubmed: 25251827
Sci Signal. 2014 Oct 28;7(349):ra102
pubmed: 25351247
N Engl J Med. 2014 Dec 4;371(23):2167-77
pubmed: 25470694
Nat Genet. 2015 Aug;47(8):864-71
pubmed: 26121087
Elife. 2015 Sep 29;4:e09811
pubmed: 26418745
Trends Biochem Sci. 2015 Nov;40(11):628-647
pubmed: 26481499
Proc Natl Acad Sci U S A. 2015 Dec 29;112(52):15862-7
pubmed: 26630010
Oncotarget. 2016 May 17;7(20):29011-22
pubmed: 27049722
Dis Model Mech. 2016 Sep 1;9(9):941-52
pubmed: 27483357
Ann Oncol. 2016 Sep;27 Suppl 3:iii4-iii15
pubmed: 27573755
Cancer Discov. 2017 Feb;7(2):137-155
pubmed: 28122866
Clin Pharmacol Ther. 2017 May;101(5):625-633
pubmed: 28182271
Cancer Lett. 2017 Aug 1;400:61-68
pubmed: 28455243
Lancet. 2017 Jul 1;390(10089):29-39
pubmed: 28501140
N Engl J Med. 2017 Aug 31;377(9):829-838
pubmed: 28586279
J Clin Oncol. 2017 Oct 1;35(28):3215-3221
pubmed: 28787259
Cancer. 2017 Dec 15;123(24):4914-4923
pubmed: 28885700
Proc Natl Acad Sci U S A. 2017 Nov 7;114(45):12027-12032
pubmed: 29078341
Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E630-E638
pubmed: 29317532
Pediatr Blood Cancer. 2018 Jul;65(7):e27055
pubmed: 29603581
Med Oncol. 2018 Apr 17;35(5):72
pubmed: 29666949
Cell Death Discov. 2018 May 10;4:56
pubmed: 29760954
Cold Spring Harb Mol Case Stud. 2018 Aug 1;4(4):
pubmed: 29907598
Ann Oncol. 2018 Nov 1;29(11):2214-2222
pubmed: 30215676
Cell. 1994 Jun 17;77(6):841-52
pubmed: 7911739
Science. 1994 Mar 4;263(5151):1281-4
pubmed: 8122112
Oncogene. 1997 Jan 30;14(4):439-49
pubmed: 9053841
Oncogene. 1997 May 8;14(18):2175-88
pubmed: 9174053